• Something wrong with this record ?

Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia

T. Stark, J. Ruda-Kucerova, FA. Iannotti, C. D'Addario, R. Di Marco, V. Pekarik, E. Drazanova, F. Piscitelli, M. Bari, Z. Babinska, G. Giurdanella, M. Di Bartolomeo, S. Salomone, A. Sulcova, M. Maccarrone, CT. Wotjak, Z. Starcuk, F. Drago, R....

. 2019 ; 146 (-) : 212-221. [pub] 20181126

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20006713

In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively. At the molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and protein expression, which might be due to reduction in DNA methylation at the gene promoter in the prefrontal cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM rats. Both the schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol (30 mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day), but not with haloperidol (0.6 mg/kg/day). These results suggest that early treatment with cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006713
003      
CZ-PrNML
005      
20230315102929.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.neuropharm.2018.11.035 $2 doi
035    __
$a (PubMed)30496751
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Stark, Tibor $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia / $c T. Stark, J. Ruda-Kucerova, FA. Iannotti, C. D'Addario, R. Di Marco, V. Pekarik, E. Drazanova, F. Piscitelli, M. Bari, Z. Babinska, G. Giurdanella, M. Di Bartolomeo, S. Salomone, A. Sulcova, M. Maccarrone, CT. Wotjak, Z. Starcuk, F. Drago, R. Mechoulam, V. Di Marzo, V. Micale,
520    9_
$a In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively. At the molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and protein expression, which might be due to reduction in DNA methylation at the gene promoter in the prefrontal cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM rats. Both the schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol (30 mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day), but not with haloperidol (0.6 mg/kg/day). These results suggest that early treatment with cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult.
650    _2
$a zvířata $7 D000818
650    _2
$a kyseliny arachidonové $x metabolismus $7 D001095
650    _2
$a kanabidiol $x farmakologie $7 D002185
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a endokanabinoidy $x metabolismus $7 D063388
650    _2
$a ethanolaminy $x metabolismus $7 D004983
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glyceridy $x metabolismus $7 D005989
650    _2
$a hipokampus $x metabolismus $7 D006624
650    _2
$a interpersonální vztahy $7 D007398
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methylazoxymethanolacetát $x farmakologie $7 D008746
650    _2
$a pohybová aktivita $x účinky léků $7 D009043
650    _2
$a kyseliny olejové $x metabolismus $7 D009829
650    _2
$a kyseliny palmitové $x metabolismus $7 D010169
650    _2
$a piperidiny $x farmakologie $7 D010880
650    _2
$a polynenasycené alkamidy $x metabolismus $7 D053284
650    _2
$a prefrontální mozková kůra $x metabolismus $7 D017397
650    _2
$a těhotenství $7 D011247
650    _2
$a zpožděný efekt prenatální expozice $x farmakoterapie $x metabolismus $7 D011297
650    _2
$a puberta $7 D011627
650    _2
$a pyrazoly $x farmakologie $7 D011720
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a receptor kanabinoidní CB1 $x metabolismus $7 D043884
650    _2
$a rozpoznávání (psychologie) $x účinky léků $7 D021641
650    _2
$a schizofrenie $x chemicky indukované $x farmakoterapie $x metabolismus $7 D012559
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Iannotti, Fabio Arturo $u Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Endocannabinoid Research Group, Naples, Italy.
700    1_
$a D'Addario, Claudio $u Faculty of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
700    1_
$a Di Marco, Roberta $u Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, School of Medicine, University of Catania, Catania, Italy.
700    1_
$a Pekarik, Vladimir $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Drazanova, Eva $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Scientific Instruments, Czech Academy of Sciences, Brno, Czech Republic.
700    1_
$a Piscitelli, Fabiana $u Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Endocannabinoid Research Group, Naples, Italy.
700    1_
$a Bari, Monica $u Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, Italy.
700    1_
$a Babinska, Zuzana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Giurdanella, Giovanni $u Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, School of Medicine, University of Catania, Catania, Italy.
700    1_
$a Di Bartolomeo, Martina $u Faculty of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
700    1_
$a Salomone, Salvatore $u Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, School of Medicine, University of Catania, Catania, Italy.
700    1_
$a Sulcova, Alexandra $u CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Maccarrone, Mauro $u Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy; European Center for Brain Research/IRCCS Santa Lucia Foundation, Rome, Italy.
700    1_
$a Wotjak, Carsten T $u Department of Stress Neurobiology & Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany.
700    1_
$a Starcuk, Zenon $u Institute of Scientific Instruments, Czech Academy of Sciences, Brno, Czech Republic.
700    1_
$a Drago, Filippo $u Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, School of Medicine, University of Catania, Catania, Italy.
700    1_
$a Mechoulam, Raphael, $u Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. $d 1930-2023 $7 xx0283446
700    1_
$a Di Marzo, Vincenzo $u Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Endocannabinoid Research Group, Naples, Italy.
700    1_
$a Micale, Vincenzo $u Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, School of Medicine, University of Catania, Catania, Italy; CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic; National Institute of Mental Health, Klecany, Czech Republic. Electronic address: vincenzomicale@inwind.it.
773    0_
$w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 146, č. - (2019), s. 212-221
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30496751 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20230315102924 $b ABA008
999    __
$a ok $b bmc $g 1525571 $s 1096769
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 146 $c - $d 212-221 $e 20181126 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options